BACKGROUND: The purpose of this study was to provide preliminary data on the effects of paroxetine and amisulpride on depressive dimensions, analyzed by factor analysis, in dysthymic patients. METHODS:One hundred and eighteen patients with DSM IV criteria for DD without concurrent major depression were enrolled in this 8-week, open study, and 100 completed it. Symptom dimensions were identified by principal components analysis with the SAS Factor procedure. RESULTS: Results of the symptom rating scales indicated that both drugs were equally effective. Response rate was 65% both in the paroxetine and the amisulpride group and the proportions of patients achieving a final HRSD score < or =7 were 46.7 and 55%, respectively. MADRS factor analysis identified two factors at baseline: the first corresponding to the global severity of depression and the second to somatic symptoms. After 8 weeks of treatment only one factor could be substantiated. At week 4 both paroxetine and amisulpride produced significant improvements on factor 1 while at week 8 mean changes of factor 1 were greater in the amisulpride-treated patients. LIMITATIONS: The main limitation was the open-label design. CONCLUSIONS: Both paroxetine and amisulpride appear to be effective in the short-term management of DD, improving its most characteristic symptoms. Copright 2002 Elsevier Science BV.
RCT Entities:
BACKGROUND: The purpose of this study was to provide preliminary data on the effects of paroxetine and amisulpride on depressive dimensions, analyzed by factor analysis, in dysthymicpatients. METHODS: One hundred and eighteen patients with DSM IV criteria for DD without concurrent major depression were enrolled in this 8-week, open study, and 100 completed it. Symptom dimensions were identified by principal components analysis with the SAS Factor procedure. RESULTS: Results of the symptom rating scales indicated that both drugs were equally effective. Response rate was 65% both in the paroxetine and the amisulpride group and the proportions of patients achieving a final HRSD score < or =7 were 46.7 and 55%, respectively. MADRS factor analysis identified two factors at baseline: the first corresponding to the global severity of depression and the second to somatic symptoms. After 8 weeks of treatment only one factor could be substantiated. At week 4 both paroxetine and amisulpride produced significant improvements on factor 1 while at week 8 mean changes of factor 1 were greater in the amisulpride-treated patients. LIMITATIONS: The main limitation was the open-label design. CONCLUSIONS: Both paroxetine and amisulpride appear to be effective in the short-term management of DD, improving its most characteristic symptoms. Copright 2002 Elsevier Science BV.
Authors: Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11 Impact factor: 5.270
Authors: Timothy J Donahue; Todd M Hillhouse; Kevin A Webster; Richard Young; Eliseu O De Oliveira; Joseph H Porter Journal: Psychopharmacology (Berl) Date: 2017-09-18 Impact factor: 4.530
Authors: Thomas J Carmody; A John Rush; Ira Bernstein; Diane Warden; Stephen Brannan; Daniel Burnham; Ada Woo; Madhukar H Trivedi Journal: Eur Neuropsychopharmacol Date: 2006-06-12 Impact factor: 4.600
Authors: Shailesh Jain; Thomas J Carmody; Madhukar H Trivedi; Carroll Hughes; Ira H Bernstein; David W Morris; Graham J Emslie; A John Rush Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-09 Impact factor: 8.829
Authors: Lena C Quilty; Jennifer J Robinson; Jean-Pierre Rolland; Filip De Fruyt; Frédéric Rouillon; R Michael Bagby Journal: Int J Methods Psychiatr Res Date: 2013-08-19 Impact factor: 4.035